The structure and function of α, β and γ-Secretase as therapeutic target enzymes into the development of Alzheimer's disease: A review.
Alzheimer's disease is a progressive neurodegenerative disorder that affects the central nervous system. There are several factors that cause AD, like, intracellular hyper-phosphorylated Tau tangles, collection of extracellular Amyloid-β42 and generation of reactive oxygen species due to mitochondrial dysfunction. This review analyses the most active target of AD and both types of AD like early-onset AD and late-onset AD. BACE1 is a β-secretase involved in the cleavage of amyloid precursor protein and the pathogenesis of Alzheimer's disease. The presenilin proteins apply a critical job in the pathogenesis of Alzheimer malady by intervening the intramembranous cleavage of amyloid precursor protein and the generation of amyloid β. The two homologous proteins PS1 and PS2 speak to the reactant subunits of particular γ-secretase edifices that intercede an assortment of cellular processes. The repeated disappointment of clinical preliminaries and the proceeded with absence of a malady changing treatment request novel, multifaceted methodologies. Natural products are common molecular platforms in drug development in AD. Many natural products are being tested in various animal model systems for their role as a potential therapeutic target for AD. Presently, there are a few theories clarifying the early mechanisms of AD pathogenesis. Recently, research growth into development in the region of nanotechnology, which utilizes macromolecular strategies to make drugs in nanoscale measurements. Nanotechnology based diagnostic tools, drug carriers offer highly sensitive for effective drug targeting in the treatment of Alzheimer disease.